Cost-of-illness in patients with moderate to severe psoriasis

A cross-sectional survey in Hungarian dermatological centres

Orsolya Balogh, Valentin Brodszky, L. Gulácsi, Emese Herédi, Krisztina Herszényi, Hajnalka Jókai, S. Kárpáti, Petra Baji, E. Remenyik, A. Szegedi, Péter Holló

Research output: Article

15 Citations (Scopus)

Abstract

Background: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results: Two-hundred patients were involved (females 32%) with a mean age of 51 (SD 13) years, 103 (52%) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86%. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p <0,001). Patients with BST had better PASI and DLQI scores (p <0.01) than the other two subgroups. Conclusions: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.

Original languageEnglish
JournalEuropean Journal of Health Economics
Volume15
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2014

Fingerprint

Cost of Illness
Psoriasis
Cross-Sectional Studies
Quality of Life
Dermatology
Costs and Cost Analysis
Therapeutics
Patient Acceptance of Health Care
Cost of illness
Hungary
Biological Availability
Economics
Demography

ASJC Scopus subject areas

  • Health Policy
  • Economics, Econometrics and Finance (miscellaneous)
  • Medicine(all)

Cite this

Cost-of-illness in patients with moderate to severe psoriasis : A cross-sectional survey in Hungarian dermatological centres. / Balogh, Orsolya; Brodszky, Valentin; Gulácsi, L.; Herédi, Emese; Herszényi, Krisztina; Jókai, Hajnalka; Kárpáti, S.; Baji, Petra; Remenyik, E.; Szegedi, A.; Holló, Péter.

In: European Journal of Health Economics, Vol. 15, No. SUPPL. 1, 2014.

Research output: Article

Balogh, Orsolya ; Brodszky, Valentin ; Gulácsi, L. ; Herédi, Emese ; Herszényi, Krisztina ; Jókai, Hajnalka ; Kárpáti, S. ; Baji, Petra ; Remenyik, E. ; Szegedi, A. ; Holló, Péter. / Cost-of-illness in patients with moderate to severe psoriasis : A cross-sectional survey in Hungarian dermatological centres. In: European Journal of Health Economics. 2014 ; Vol. 15, No. SUPPL. 1.
@article{4811270842e44ad29bbded3a7701e973,
title = "Cost-of-illness in patients with moderate to severe psoriasis: A cross-sectional survey in Hungarian dermatological centres",
abstract = "Background: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results: Two-hundred patients were involved (females 32{\%}) with a mean age of 51 (SD 13) years, 103 (52{\%}) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86{\%}. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p <0,001). Patients with BST had better PASI and DLQI scores (p <0.01) than the other two subgroups. Conclusions: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.",
keywords = "Biological treatments, Cost-of-illness, Psoriasis, Quality of life",
author = "Orsolya Balogh and Valentin Brodszky and L. Gul{\'a}csi and Emese Her{\'e}di and Krisztina Hersz{\'e}nyi and Hajnalka J{\'o}kai and S. K{\'a}rp{\'a}ti and Petra Baji and E. Remenyik and A. Szegedi and P{\'e}ter Holl{\'o}",
year = "2014",
doi = "10.1007/s10198-014-0599-z",
language = "English",
volume = "15",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Cost-of-illness in patients with moderate to severe psoriasis

T2 - A cross-sectional survey in Hungarian dermatological centres

AU - Balogh, Orsolya

AU - Brodszky, Valentin

AU - Gulácsi, L.

AU - Herédi, Emese

AU - Herszényi, Krisztina

AU - Jókai, Hajnalka

AU - Kárpáti, S.

AU - Baji, Petra

AU - Remenyik, E.

AU - Szegedi, A.

AU - Holló, Péter

PY - 2014

Y1 - 2014

N2 - Background: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results: Two-hundred patients were involved (females 32%) with a mean age of 51 (SD 13) years, 103 (52%) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86%. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p <0,001). Patients with BST had better PASI and DLQI scores (p <0.01) than the other two subgroups. Conclusions: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.

AB - Background: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results: Two-hundred patients were involved (females 32%) with a mean age of 51 (SD 13) years, 103 (52%) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86%. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p <0,001). Patients with BST had better PASI and DLQI scores (p <0.01) than the other two subgroups. Conclusions: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.

KW - Biological treatments

KW - Cost-of-illness

KW - Psoriasis

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84905708758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905708758&partnerID=8YFLogxK

U2 - 10.1007/s10198-014-0599-z

DO - 10.1007/s10198-014-0599-z

M3 - Article

VL - 15

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - SUPPL. 1

ER -